Pfizer has introduced the first and only ABRYSVO™ vaccine designed to combat lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth to six months.
ABRYSVO stands out to be a unique vaccine composed of two preF proteins meticulously selected to optimise protection against both RSV A and B strains, and it has shown a strong track record of safety and efficacy.
This groundbreaking vaccine is administered through active immunisation of pregnant individuals during the gestational period of 32 through 36 weeks.
The approval of ABRYSVO as the sole maternal immunisation to safeguard newborns immediately from birth up to six months against RSV is a momentous achievement for public health.
RSV is a highly contagious virus that poses a significant global threat as a common cause of respiratory illnesses. This virus can severely impact the respiratory system of infected individuals, potentially leading to life-threatening conditions.
In the United States alone, there are approximately 500,000 to 600,000 cases of LRTD attributed to RSV each year, making it a leading cause of hospitalisations among children under one year of age.
Recognising the exceptional potential of ABRYSVO, the U.S. Food and Drug Administration (FDA) has granted it breakthrough therapy designation for the prevention of RSV-associated lower respiratory tract illnesses in infants from birth up to six months of age through active immunisation of pregnant women.